CRISPR Therapeutics (CRSP)
(Real Time Quote from BATS)
$54.08 USD
-1.59 (-2.85%)
Updated Feb 8, 2023 01:00 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Detailed Estimates
Estimates
Exp Earnings Date | 2/21/23 |
---|---|
Current Quarter | -2.32 |
EPS Last Quarter | -2.24 |
Last EPS Surprise | 2.61% |
ABR | 1.99 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -9.25 |
Next Year | -8.21 |
EPS (TTM) | -8.80 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (12/2022) |
Next Qtr (3/2023) |
Current Year (12/2022) |
Next Year (12/2023) |
|
---|---|---|---|---|
Zacks Consensus Estimate | 12.18M | 2.19M | 9.36M | 193.46M |
# of Estimates | 8 | 5 | 12 | 11 |
High Estimate | 90.00M | 6.60M | 91.19M | 852.50M |
Low Estimate | 0.05M | 0.50M | 1.00M | 1.50M |
Year ago Sales | 12.90M | 0.94M | 914.96M | 9.36M |
Year over Year Growth Est. | -5.60% | 132.77% | -98.98% | 1,966.16% |
Earnings Estimates
Current Qtr (12/2022) |
Next Qtr (3/2023) |
Current Year (12/2022) |
Next Year (12/2023) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -2.32 | -2.36 | -9.25 | -8.21 |
# of Estimates | 12 | 7 | 12 | 14 |
Most Recent Consensus | -2.59 | -2.33 | -9.55 | -9.20 |
High Estimate | -1.33 | -1.89 | -8.27 | -2.22 |
Low Estimate | -2.66 | -2.59 | -9.55 | -11.97 |
Year ago EPS | -1.84 | -2.32 | 4.70 | -9.25 |
Year over Year Growth Est. | -26.09% | -1.72% | -296.81% | 11.22% |
Agreement - Estimate Revisions
Current Qtr (12/2022) |
Next Qtr (3/2023) |
Current Year (12/2022) |
Next Year (12/2023) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 0 | 0 |
Up Last 60 Days | 0 | 0 | 0 | 1 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 1 |
Down Last 60 Days | 0 | 0 | 0 | 1 |
Magnitude - Consensus Estimate Trend
Current Qtr (12/2022) |
Next Qtr (3/2023) |
Current Year (12/2022) |
Next Year (12/2023) |
|
---|---|---|---|---|
Current | -2.32 | -2.36 | -9.25 | -8.21 |
7 Days Ago | -2.32 | -2.36 | -9.25 | -8.21 |
30 Days Ago | -2.32 | -2.37 | -9.25 | -8.21 |
60 Days Ago | -2.32 | -2.37 | -9.25 | -8.21 |
90 Days Ago | -2.28 | -2.31 | -9.23 | -7.89 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (12/2022) |
Next Qtr (3/2023) |
Current Year (12/2022) |
Next Year (12/2023) |
|
---|---|---|---|---|
Most Accurate Estimate | -2.32 | -2.33 | -9.25 | -9.20 |
Zacks Consensus Estimate | -2.32 | -2.36 | -9.25 | -8.21 |
Earnings ESP | 0.00% | 1.39% | 0.00% | -12.03% |
Surprise - Reported Earnings History
Quarter Ending (9/2022) |
Quarter Ending (6/2022) |
Quarter Ending (3/2022) |
Quarter Ending (12/2021) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -2.24 | -2.40 | -2.32 | -1.84 | NA |
Estimate | -2.30 | -2.23 | -1.91 | -1.74 | NA |
Difference | 0.06 | -0.17 | -0.41 | -0.10 | -0.16 |
Surprise | 2.61% | -7.62% | -21.47% | -5.75% | -8.06% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more